OXURION N.V.

ISIN: BE0003846632 WKN: - Asset Class: Stock



Company Profile

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA brand name. The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium.

Financial figures, Fiscal year: from 01.01. to 31.12.

| | 20 | 23 | 20 | 22 | 20 | 21 |
|--------------------------------|-----------|------------------------|------------|------------------------|------------|------------------------|
| Financial figures | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 2,740,000 | | 7,106,000 | | 13,409,000 | |
| Common stock capital | | 72,993,000 | | 65,443,000 | | 46,029,000 |
| Fixed assets | 3,810,000 | | 4,887,000 | | 5,467,000 | |
| Equity capital of a company | | -13,186,000 | | -4,583,000 | | -1,108,000 |
| Cash and cash equivalents | 1,624,000 | | 3,496,000 | | 9,740,000 | |
| Accrued liabilities | | 12,000 | | 159,000 | | 594,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 19,607,000 | | 12,349,000 | | 10,913,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 129,000 | | 4,227,000 | | 9,071,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 0 | | 0 | | 0 |
| Total assets | 6,550,000 | 6,550,000 | 11,993,000 | 11,993,000 | 18,876,000 | 18,876,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|----------|----------|------------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 19 | 27 | 42 |
| Equity ratio | -201.31% | -38.21% | -6.03% |
| Debt-equity ratio | -149.67% | -361.68% | -1,758.70% |

Others

| | 2023 | 2022 | 2021 |
|------------------|--------|--------|--------|
| Tax Expense Rate | -0.02% | -0.02% | -0.01% |

OXURION N.V.

ISIN: BE0003846632 WKN: - Asset Class: Stock

| Income statement | | | |
|--|-------------|-------------|-------------|
| | 2023 | 2022 | 2021 |
| Turnover | 263,000 | 595,000 | 1,128,000 |
| Net income | -18,969,000 | -31,685,000 | -29,158,000 |
| EBIT | -16,999,000 | -30,325,000 | -28,862,000 |
| Operating income before taxes | -18,966,000 | -31,686,000 | -29,592,000 |
| Cash Flow | -10,080,000 | -20,016,000 | -27,155,000 |
| Net interest income | -1,967,000 | -1,361,000 | -730,000 |
| Research and development expenses | 9,754,000 | 15,684,000 | 20,196,000 |
| Income taxes | 3,000 | 7,000 | 3,000 |
| Result from investments in subsidaries, associates and other | 0 | 0 | 0 |
| Revenues per employee | 13,842 | 22,037 | 26,857 |

| Board of Directors | |
|-----------------------------|-------------------------------|
| Charles Paris de Bollardire | Chairman of Supervisory Board |
| Anat Loewenstein | Member of Supervisory Board |
| James Hartmann | Member of Supervisory Board |
| Nathalie Laarakker | Member of Supervisory Board |

| Members of Management Board | | | |
|-----------------------------|-------------------------------|--|--|
| Tom Graney | Chairman of Managing Board | | |
| Andy De Deene | Member of Executive Committee | | |
| Kathleen Paisley | Member of Executive Committee | | |
| Michael Dillen | Member of Executive Committee | | |